ACE and COVID-19: An area of ongoing interest, which was not rigorously investigated, is whether ACE inhibitors or angiotensin receptors blocker effect mortality in the COVID-19 population; however, recent randomized controlled trials have not shown a moratlity benefit [15, 16].